Suzhou, China, May 6th, 2024——Accro Bioscience (Suzhou) Limited (Accropeutics) announced today that the first psoriasis patient has been dosed in the phase 2 clinical trial of the TYK2/JAK1 inhibitor AC-201 in China. This study is a multicenter, randomized, double-blind, parallel group, placebo-controlled phase II clinical trial to evaluate the efficacy, safety, and pharmacokinetic characteristics of AC-201 in subjects with moderate to severe plaque psoriasis.
Suzhou China, April 26, 2024 - Accro Bioscience (Suzhou) Limited (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announces positive results at the completion of the Phase I study of its drug candidate AC-101 in healthy human subjects. The Phase I trial was a single center, randomized, double-blind, placebo-controlled, single and multiple ascending dose study following oral administration in healthy human subjects, to evaluate the safety, tolerability, pharmacokinetics and the effects of food of AC-101.
Suzhou China, December 25, 2023 —— Accro Bioscience (Suzhou) Limited (Accropeutics) announced that its RIPK1 inhibitor AC-003 capsules for the treatment of acute Graft-versus-Host Disease (aGvHD) has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).
Suzhou China, September 8, 2023 —— Accro Bioscience (Suzhou) Limited (Accropeutics) announced today that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the National Medical Products Administration (NMPA) to launch clinical phase 1 trial in China. AC-201 was approved for clinical trials by HREC in Australia in May 2023, and the Phase 1 clinical trial in Australia is currently underway.
Suzhou China, June 21, 2023 —— Accropeutics Bioscience announced today that its oral small-molecule RIPK2 inhibitor AC-101 has been approved by the National Medical Products Administration (NMPA) to launch clinical phase I trial in China. The design is a randomized, double-blind, placebo-controlled, single dose, and multiple dose incremental phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-101 in healthy adults. This is the forth clinical approval obtained by Accropeutics Bioscience this year.
Suzhou China, May 12, 2023 —— Accro Bioscience (Suzhou) Limited announced today that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch clinical phase I trial in Australia. The design is a randomized, double-blind, placebo-controlled, single dose, and multi dose incremental phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults.
